Galena Biopharma (NASDAQ: GALE) announced the first patient has been dosed in the GALE-401, or Anagrelide Controlled Release (CR), Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE